XENON PHARMACEUTICALS INC. Share-based Payment Arrangement, Expense
XENON PHARMACEUTICALS INC. (XENE) reported Share-based Payment Arrangement, Expense of $16.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $16.73M, a 22.02% increase year-over-year.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $16.89M, a 38.77% increase year-over-year.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $14.12M, a 3.79% increase year-over-year.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $13.71M, a 5.41% increase year-over-year.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for fiscal 2025 was $53.71M, a 5.90% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for fiscal 2024 was $50.72M, a 56.67% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for fiscal 2023 was $32.37M, a 58.87% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. share-based payment arrangement, expense for fiscal 2022 was $20.38M, a 103.41% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.73M 10-Q · filed 2026-08-06 | $33.63M 10-Q · filed 2026-08-06 | $47.74M derived: sum of 3 quarters · filed 2026-08-06 | $61.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $16.89M 10-Q · filed 2026-05-07 | $31.01M derived: sum of 2 quarters · filed 2026-05-07 | $44.71M derived: sum of 3 quarters · filed 2026-05-07 | $58.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.82M derived: sum of 2 quarters · filed 2026-02-26 | $41.53M derived: sum of 3 quarters · filed 2026-08-06 | $53.71M 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.71M 10-Q · filed 2025-11-03 | $27.42M derived: sum of 2 quarters · filed 2026-08-06 | $39.59M 10-Q · filed 2025-11-03 | $53.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.71M 10-Q · filed 2026-08-06 | $25.89M 10-Q · filed 2026-08-06 | $39.49M derived: sum of 3 quarters · filed 2026-08-06 | $52.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.17M 10-Q · filed 2026-05-07 | $25.77M derived: sum of 2 quarters · filed 2026-05-07 | $38.77M derived: sum of 3 quarters · filed 2026-05-07 | $53.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.60M derived: sum of 2 quarters · filed 2026-02-26 | $41.32M derived: sum of 3 quarters · filed 2026-02-26 | $50.72M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.00M 10-Q · filed 2025-11-03 | $27.72M derived: sum of 2 quarters · filed 2025-11-03 | $37.12M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $14.72M 10-Q · filed 2025-08-11 | $24.12M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $9.40M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $32.37M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $20.38M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $10.02M 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $5.68M 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $2.94M 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $2.76M 10-K · filed 2020-03-09 | |||
| 2017-12-31 | $2.24M 10-K · filed 2019-03-06 | |||
| 2016-12-31 | $2.16M 10-K · filed 2018-03-07 | |||
| 2015-12-31 | $3.73M 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $760.00K 10-K · filed 2017-03-08 | |||
| 2013-12-31 | $575.00K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |